# US 2013/0157972 A1 · Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157972 A1
- Document ID: US20130157972A1
- Status: Published application
- Kind: A1
- Application number: 13/453,834
- Filed: 2012-04-23
- Published: 2013-06-20
- Earliest claimed: 2004-03-29
- Assignees: University of South Florida
- Inventors: Jin Q. CHENG; Said M. Sebti
- Web page: https://patentgrep.com/patent/US20130157972A1

## CPC

- A61K 38/05: Dipeptides
- A61K 31/69: Boron compounds
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A diagnostic method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising:
A. obtaining a biological sample from the subject;
B. determining whether the sample overexpresses AKT kinase;
C. if said sample overexpresses AKT kinase,
1. administering to said subject:
i. at least one compound of formula I selected from the group consisting of the following compounds:
wherein each R2′, R3′, and R5′ is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R2′, R3′ or R5′ is independently H or mono-, di- or tri-phosphate;
wherein Rx and Ry are independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and
wherein R1 and R2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl;
ii. a compound of the formula V:
wherein
R1, R2, R3, R4 and R5 each are independently H, optionally halogenated, substituted straight chained, branched or cyclic alkyl (including lower alkyl), alkoxyl, alkenyl, or alkynyl, aryl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl; and
iii. a pharmaceutically acceptable carrier.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the compound of formula I is triciribine.

### Claim 29 (depends on 27)

The composition of claim 27, wherein the compound of formula I is triciribine phosphate.

### Claim 30 (depends on 27)

The composition of claim 27, wherein the compound of formula I is triciribine phosphonate.

### Claim 31 (depends on 27)

The composition of claim 27, wherein the compound of formula I is present in a dose amount of at least 20 mg/m2.

### Claim 32 (depends on 27)

The composition of claim 27, wherein the compound of formula I is present in an amount of at least 10 mg/m2.

### Claim 33 (depends on 27)

The composition of claim 27, suitable for parenteral administration.

### Claim 34 (depends on 27)

The composition of claim 27, wherein the parenteral administration is intravenous administration.

### Claim 35 (depends on 27)

The composition of claim 27, suitable for oral administration.

### Claim 36 (depends on 27)

The composition of claim 27, suitable for topical administration.

### Claim 37 (depends on 27)

The composition of claim 27, wherein the compound of formula V is:
or a salt thereof.

### Claim 38 (depends on 27)

The composition of claim 27, wherein the compound of formula V or a salt thereof is present in an amount from about 1 mg to about 1000 mg.

### Claim 39 (depends on 27)

The composition of claim 27, wherein the compound of formula V or a salt thereof is present in an amount from about 100 mg to about 500 mg.

### Claim 40 (depends on 27)

The composition of claim 27, wherein the compound of formula V or a salt thereof is present in an amount from about 200 mg to about 450 mg.

### Claim 41 (depends on 27)

The composition of claim 27, wherein the compound of formula V or a salt thereof is present in an amount of about 400 mg.

### Claim 42 (depends on 27)

The composition of claim 27, wherein the administration of a compound of formula I and the compound of formula V is a single composition.

### Claim 43 (depends on 27)

The composition of claim 27, wherein the administration of a compound of formula I and the compound of formula V is concurrently administered.

### Claim 44 (depends on 27)

The composition of claim 27, wherein the administration of a compound of formula I is followed by the administration of the compound of formula V.

### Claim 45 (depends on 27)

The composition of claim 27, wherein the administration of the compound of formula V is followed by the administration of a compound of the compound of formula V I.
